Background
NSCLC, colorectal cancer, CRC, non-small-cell lung cancer, PDAC, tumors, pancreatic ductal adenocarcinoma
PANCREATIC DUCTAL ADENOCARCINOMA, COLORECTAL CANCER, TUMORS, NSCLC
CD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab in patients with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or epidermal growth factor receptor-mutant non-small-cell lung cancer (NSCLC).